


SEP 25 2006

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the structural formula (I):



or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein in Formula (I) above:

X, Y and Z can be the same or different and each is independently selected from the group consisting of $-\text{CH}_2-$, $-\text{CH}(\text{alkyl})-$ and $-\text{C}(\text{alkyl})_2-$;

Q^1 and Q^2 can be the same or different and each is independently selected from the group consisting of H, -G, $-(\text{C}_1-\text{C}_{30} \text{ alkylene})-\text{G}$, $-\text{OR}^6$, $-\text{OC}(\text{O})\text{R}^6$, $-\text{OC}(\text{O})\text{OR}^9$, $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$, and $-\text{L}-\text{M}$;

Q^3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -G, $-(\text{C}_1-\text{C}_{30} \text{ alkylene})-\text{G}$, $-\text{OR}^6$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OR}^6$, $-\text{C}(\text{O})\text{R}^6$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{R}^6$, $-\text{C}(\text{O})\text{OR}^6$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{OR}^6$, $-\text{OC}(\text{O})\text{R}^6$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OC}(\text{O})\text{R}^6$, $-\text{OC}(\text{O})\text{OR}^9$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OC}(\text{O})\text{OR}^9$, $-\text{CH}=\text{CH}-\text{C}(\text{O})\text{R}^6$, $-\text{CH}=\text{CH}-\text{C}(\text{O})\text{OR}^6$, $-\text{C}\equiv\text{C}-\text{C}(\text{O})\text{OR}^6$, $-\text{C}\equiv\text{C}-\text{C}(\text{O})\text{R}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OR}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{R}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{OR}^6$, -CN, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{NR}^6\text{R}^7$, $-\text{O}-\text{C}(\text{O})\text{NR}^6\text{NR}^7\text{C}(\text{O})\text{OR}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{NR}^6\text{NR}^7\text{C}(\text{O})\text{OR}^6$, $-\text{O}-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})(\text{aryl})-\text{N}_3$, $-\text{OC}(\text{O})-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{OR}^6$, $-\text{C}(\text{O})\text{NR}^6\text{R}^7$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{C}(\text{O})\text{NR}^6\text{R}^7$, $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{OC}(\text{O})\text{NR}^6\text{R}^7$, $-\text{NO}_2$, $-\text{NR}^6\text{R}^7$, $-(\text{C}_1-\text{C}_{10} \text{ alkylene})-\text{NR}^6\text{R}^7$,

Reply under 37 CFR 1.116
 Expedited Procedure
 Technology Center 1624
 Attorney Docket No. CV06039US01

-O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹,
 -NR⁶C(O)NR⁷R⁸, -NR⁶S(O)₀₋₂R⁹, -N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷,
 -C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷, -S(O)₀₋₂R⁹, -O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
 -OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl), -P(O)(OR¹⁰)₂,
 -(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy,
 alkoxyacylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl,
 aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy,
 heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl,
 heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;

Q⁴ is 1 to 5 substituents independently selected from the group consisting of alkyl,
 alkenyl, alkynyl, -G, -(C₁-C₃₀ alkylene)-G, -OR⁶, -(C₁-C₁₀ alkylene)-OR⁶, -C(O)R⁶,
 -(C₁-C₁₀ alkylene)-C(O)R⁶, -C(O)OR⁶, -(C₁-C₁₀ alkylene)-C(O)OR⁶, -OC(O)R⁶,
 -(C₁-C₁₀ alkylene)-OC(O)R⁶, -OC(O)OR⁹, -(C₁-C₁₀ alkylene)-OC(O)OR⁹, -CH=CH-C(O)R⁶,
 -CH=CH-C(O)OR⁶, -C≡C-C(O)OR⁶, -C≡C-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-OR⁶,
 -O-(C₁-C₁₀ alkylene)-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-C(O)OR⁶, -CN,
 -O-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -O-C(O)NR⁶NR⁷C(O)OR⁶,
 -O-(C₁-C₁₀ alkylene)-C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)(aryl)-N₃,
 -OC(O)-(C₁-C₁₀ alkylene)-C(O)OR⁶, -C(O)NR⁶R⁷, -(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
 -OC(O)NR⁶R⁷, -(C₁-C₁₀ alkylene)-OC(O)NR⁶R⁷, -NO₂, -NR⁶R⁷, -(C₁-C₁₀ alkylene)-NR⁶R⁷,
 -O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹, -NR⁶C(O)NR⁷R⁸,
 -NR⁶S(O)₀₋₂R⁹, -N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷, -C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷,
 -S(O)₀₋₂R⁹, -O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
 -OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl), -P(O)(OR¹⁰)₂,
 -(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy,
 alkoxyacylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl,
 aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy,

{W0301937.1}

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;

Q^5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -G, -(C₁-C₃₀ alkylene)-G, -OR⁶, -(C₁-C₁₀ alkylene)-OR⁶, -C(O)R⁶, -(C₁-C₁₀ alkylene)-C(O)R⁶, -C(O)OR⁶, -(C₁-C₁₀ alkylene)-C(O)OR⁶, -OC(O)R⁶, -(C₁-C₁₀ alkylene)-OC(O)R⁶, -OC(O)OR⁹, -(C₁-C₁₀ alkylene)-OC(O)OR⁹, -CH=CH-C(O)R⁶, -CH=CH-C(O)OR⁶, -C≡C-C(O)OR⁶, -C≡C-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-C(O)OR⁶, -CN, -O-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -O-C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)(aryl)-N₃, -OC(O)-(C₁-C₁₀ alkylene)-C(O)OR⁶, -C(O)NR⁶R⁷, -(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -OC(O)NR⁶R⁷, -(C₁-C₁₀ alkylene)-OC(O)NR⁶R⁷, -NO₂, -NR⁶R⁷, -(C₁-C₁₀ alkylene)-NR⁶R⁷, -O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹, -NR⁶C(O)NR⁷R⁸, -NR⁶S(O)₀₋₂R⁹, -N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷, -C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷, -S(O)₀₋₂R⁹, -O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl), -P(O)(OR¹⁰)₂, -(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyaryloxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;


wherein optionally one or more carbon atoms of the -(C₁-C₃₀ alkylene)- radical of Q¹, Q², Q³, Q⁴ and Q⁵ is independently replaced by -O-, -C(O)-, -CH=CH-, -C≡C-, -N(alkyl)-, -N(alkylaryl)- or -NH-;

G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

comprising 2 to 9 amino acids, trialkylammoniumalkyl ~~saltradiol~~ and $-S(O)_2-OH$, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with $-L-M$;





L is selected from the group consisting of







wherein Me is methyl;

M is selected from the group of moieties consisting of

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01




Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01



{W0301957.1}

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01



pharmaceutically acceptable salts of the moieties (M1) and (M3) to (M10) and free acids of the moieties (M1) and (M3) to (M10);

R^2 and R^3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;

R^6 , R^7 and R^8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and

each R^9 is independently alkyl, aryl or arylalkyl.

each R^{10} is independently H or alkyl;

q is 0 or 1;

r is 0 or 1;

m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;

x1 is 1 to 10;

x2 is 1 to 10;

x3 is 1 to 10;

x4 is 1 to 10;

x5 is 1 to 10;

x6 is 1 to 10; and

x7 is 1 to 10;

x8 is 1 to 10;

{W0301957.1}

8

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

x9 is 1 to 10;
x10 is 1 to 10;
x11 is 1 to 10;
x12 is 1 to 10;
x13 is 1 to 10;
x14 is 1 to 10;
x15 is 1 to 10; and
x16 is 1 to 10;
x17 is 1 to 10; and
x18 is 1 to 10;

with the proviso that at least one of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is -L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M, and wherein each of the above alkyl, alkenyl, alkynyl, alkylene, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyaryloxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, or heterocyclylcarbonylalkoxy groups, when present, is independently substituted or unsubstituted.

2. (Original) The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is $-\text{CH}_2-$.

3. (Original) The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is $-\text{CH}_2-$, Q^1 is $-\text{OR}^6$, wherein R^6 is hydrogen and Q^5 is fluorine.

{W0301937.1}

9

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

4. (Previously Presented) The compound according to claim 1, wherein R^1 and R^3 are each hydrogen.

5. (Original) The compound according to claim 1, wherein Q^1 and Q^2 are each independently selected from the group consisting of $-OR^6$, $-O(CO)R^6$, $-O(CO)OR^9$ and $-O(CO)NR^6R^7$.

6. (Original) The compound according to claim 1, wherein Q^4 is halo or $-OR^6$.


7. (Original) The compound according to claim 1, wherein Q^1 is $-OR^6$ wherein R^6 is H.

8. (Original) The compound according to claim 1, wherein Q^1 , Q^2 , Q^3 , Q^4 or Q^5 is $-L-M$.

9. (Previously Presented) The compound according to claim 1, wherein Q^1 , Q^2 , Q^3 , Q^4 or Q^5 is $-G$ or $-(C_1-C_{30} \text{ alkylene})-G$.

10. (Withdrawn) The compound according to claim 1, wherein G is selected from the group consisting of:

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01



wherein R, R^a and R^b can be the same or different and each is independently selected from the group consisting of H, -OH, halo, -NH₂, azido, alkoxyalkoxy or -W-R³⁰;

W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R³¹)-, -NH-C(O)-N(R³¹)- and -O-C(S)-N(R³¹)-;

R^{2a} and R^{6a} can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;

R^{3a}, R^{4a}, R^{5a}, R^{7a}, R^{3b} and R^{4b} can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, -C(O)alkyl and -C(O)aryl;

R³⁰ is independently selected from the group consisting of R³²-substituted T, R³²-substituted-T-alkyl, R³²-substituted-alkenyl, R³²-substituted-alkyl, R³²-substituted-cycloalkyl and R³²-substituted-cycloalkylalkyl;

R³¹ is independently selected from the group consisting of H and alkyl;

T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;

R³² is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, -OH, phenoxy, -CF₃, -NO₂, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -N(CH₃)₂, -C(O)-NHalkyl, -C(O)-N(alkyl)₂, -C(O)-alkyl, -C(O)-


{W0301957.1}

11

Reply under 37 CFR 1.116
 Expedited Procedure
 Technology Center 1624
 Attorney Docket No. CV06039US01

alkoxy and pyrrolidinylcarbonyl; or R^{32} is a covalent bond and R^{31} , the nitrogen to which it is attached and R^{32} form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxy carbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group.

11. (Withdrawn) The compound according to claim 10, wherein G is selected from:




Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

wherein Ac is acetyl and Ph is phenyl.

12. (Previously Presented) The compound according to claim 1, wherein optionally one or more carbon atoms of the $-(C_1-C_{30} \text{ alkylene})-$ radical of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is independently replaced by $-O-$.

13. (Original) The compound according to claim 1, which is



(II).

14. (Currently Amended) A pharmaceutical composition for the treatment of atherosclerosis, hypercholesterolemia, sitosterolemia, ~~diabetes mellitus, obesity, stroke,~~ lowering a concentration of cholesterol, phytosterol or 5α -stanol in plasma of a ~~mammal, treating demyelination or treating Alzheimer's disease and/or regulating levels of amyloid β peptides in a~~ subject comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.


15. (Original) A pharmaceutical composition comprising a cholesterol-lowering effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.

Reply under 37 CFR 1.116
 Expedited Procedure
 Technology Center 1624
 Attorney Docket No. CV06039US01

16. (Currently Amended) A method of treating atherosclerosis, hypercholesterolemia, sitosterolemia, ~~diabetes mellitus, obesity, stroke,~~ lowering a concentration of cholesterol, phytosterol or 5 α -stanol in plasma of a ~~mammal, treating demyelination or treating Alzheimer's disease or regulating a level of an amyloid β peptide in a~~ subject comprising the step of administering to a subject in need of such treatment an effective amount of a compound of claim 1.

17. (Original) A method of lowering cholesterol level in plasma of a mammal in need of such treatment comprising administering a pharmaceutically effective amount of the compound of claim 1.

18. (Currently Amended) A compound represented by the structural formula (IA):



or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (IA),

wherein in Formula (IA) above:

X, Y and Z can be the same or different and each is independently selected from the group consisting of -CH₂-, -CH(alkyl)- and -C(alkyl)₂-;

Q¹ and Q² can be the same or different and each is independently selected from the group consisting of H, -G, -(C₁-C₃₀ alkylene)-G, -OR⁶, -OC(O)R⁶, -OC(O)OR⁹, -OC(O)NR⁶R⁷, and -L-M;

Q³ is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -G, -(C₁-C₃₀ alkylene)-G, -OR⁶, -(C₁-C₁₀ alkylene)-OR⁶, -C(O)R⁶,

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

- $(C_1-C_{10} \text{ alkylene})-C(O)R^6$, $-C(O)OR^6$, $-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-OC(O)R^6$,
 $-(C_1-C_{10} \text{ alkylene})-OC(O)R^6$, $-OC(O)OR^9$, $-(C_1-C_{10} \text{ alkylene})-OC(O)OR^9$, $-CH=CH-C(O)R^6$,
 $-CH=CH-C(O)OR^6$, $-C\equiv C-C(O)OR^6$, $-C\equiv C-C(O)R^6$, $-O-(C_1-C_{10} \text{ alkylene})-OR^6$,
 $-O-(C_1-C_{10} \text{ alkylene})-C(O)R^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-CN$,
 $-O-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-O-C(O)NR^6NR^7C(O)OR^6$,
 $-O-(C_1-C_{10} \text{ alkylene})-C(O)NR^6NR^7C(O)OR^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)(\text{aryl})-N_3$,
 $-OC(O)-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-C(O)NR^6R^7$, $-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$,
 $-OC(O)NR^6R^7$, $-(C_1-C_{10} \text{ alkylene})-OC(O)NR^6R^7$, $-NO_2$, $-NR^6R^7$, $-(C_1-C_{10} \text{ alkylene})-NR^6R^7$,
 $-O-(C_2-C_{10} \text{ alkylene})-NR^6R^7$, $-NR^6C(O)R^7$, $-NR^6C(O)OR^9$, $-NR^6C(O)NR^7R^8$, $-NR^6S(O)_{0-2}R^9$,
 $-N(S(O)_{0-2}R^9)_2$, $-CHNOR^6$, $-C(O)NR^6R^7$, $-C(O)NR^6NR^6R^7$, $-S(O)_{0-2}NR^6R^7$, $-S(O)_{0-2}R^9$,
 $-O-C(O)-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-OC(O)-(C_1-C_{10} \text{ alkylene})-NR^6C(O)O-(\text{alkylaryl})$,
 $-P(O)(OR^{10})_2$, $-(C_1-C_{10} \text{ alkylene})-OSi(\text{alkyl})_3$, $-CF_3$, $-OCF_3$, halo, alkoxyalkoxy,
 alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyaryloxy, alkoxyiminoalkyl, alkylidioyl,
 allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl,
 benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl,
 heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and $-L-M$;

Q^4 is 1 to 5 substituents independently selected from the group consisting of alkyl,
 alkenyl, alkynyl, $-G$, $-(C_1-C_{30} \text{ alkylene})-G$, $-OR^6$, $-(C_1-C_{10} \text{ alkylene})-OR^6$, $-C(O)R^6$,
 $-(C_1-C_{10} \text{ alkylene})-C(O)R^6$, $-C(O)OR^6$, $-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-OC(O)R^6$,
 $-(C_1-C_{10} \text{ alkylene})-OC(O)R^6$, $-OC(O)OR^9$, $-(C_1-C_{10} \text{ alkylene})-OC(O)OR^9$, $-CH=CH-C(O)R^6$,
 $-CH=CH-C(O)OR^6$, $-C\equiv C-C(O)OR^6$, $-C\equiv C-C(O)R^6$, $-O-(C_1-C_{10} \text{ alkylene})-OR^6$,
 $-O-(C_1-C_{10} \text{ alkylene})-C(O)R^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-CN$,
 $-O-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-O-C(O)NR^6NR^7C(O)OR^6$,
 $-O-(C_1-C_{10} \text{ alkylene})-C(O)NR^6NR^7C(O)OR^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)(\text{aryl})-N_3$,
 $-OC(O)-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-C(O)NR^6R^7$, $-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$,

{W0301957.1}

15

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

-OC(O)NR⁶R⁷, -(C₁-C₁₀ alkylene)-OC(O)NR⁶R⁷, -NO₂, -NR⁶R⁷, -(C₁-C₁₀ alkylene)-NR⁶R⁷,
-O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹, -NR⁶C(O)NR⁷R⁸, -NR⁶S(O)₀₋₂R⁹,
-N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷, -C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷, -S(O)₀₋₂R⁹,
-O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl),
-P(O)(OR¹⁰)₂, -(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy,
alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkylidioyl,
allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl,
benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl,
heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;

Q⁵ is 1 to 5 substituents independently selected from the group consisting of alkyl,
alkenyl, alkynyl, -G, -(C₁-C₃₀ alkylene)-G, -OR⁶, -(C₁-C₁₀ alkylene)-OR⁶, -C(O)R⁶,
-(C₁-C₁₀ alkylene)-C(O)R⁶, -C(O)OR⁶, -(C₁-C₁₀ alkylene)-C(O)OR⁶, -OC(O)R⁶,
-(C₁-C₁₀ alkylene)-OC(O)R⁶, -OC(O)OR⁹, -(C₁-C₁₀ alkylene)-OC(O)OR⁹, -CH=CH-C(O)R⁶,
-CH=CH-C(O)OR⁶, -C≡C-C(O)OR⁶, -C≡C-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-OR⁶,
-O-(C₁-C₁₀ alkylene)-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-C(O)OR⁶, -CN,
-O-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -O-C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₀₁-C₁₀ alkylene)-
C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)(aryl)-N₃, -OC(O)-(C₁-C₁₀ alkylene)-
C(O)OR⁶, -C(O)NR⁶R⁷, -(C₀₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -OC(O)NR⁶R⁷,
-(C₁-C₁₀ alkylene)-OC(O)NR⁶R⁷, -NO₂, -NR⁶R⁷, -(C₁-C₁₀ alkylene)-NR⁶R⁷,
-O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹,
-NR⁶C(O)NR⁷R⁸, -NR⁶S(O)₀₋₂R⁹, -N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷,
-C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷, -S(O)₀₋₂R⁹, -O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
-OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl), -P(O)(OR¹⁰)₂,
-(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy,
alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl,
aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy,


Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;

wherein optionally one or more carbon atoms of the $-(C_1-C_{30} \text{ alkylene})-$ radical of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is independently replaced by $-O-$, $-C(O)-$, $-CH=CH-$, $-C\equiv C-$, $-N(\text{alkyl})-$, $-N(\text{alkylaryl})-$ or $-NH-$;

G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl ~~saltradiol~~ and $-S(O)_2-OH$, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with $-L-M$;


L is selected from the group consisting of




wherein Me is methyl;

M is selected from the group of moieties consisting of


Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01




(M11),




(M12),




(M13),




(M14),



(M15),




(M16),




(M17),


Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01




(M19),




(M20),




(M21),




(M22),




(M23),



(M24),




(M25),



(M26),

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01



and pharmaceutically acceptable salts of moieties (M1) to (M33);

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

R^2 and R^3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;

R^6 , R^7 and R^8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and

each R^9 is independently alkyl, aryl or arylalkyl.

each R^{10} is independently H or alkyl;

q is 0 or 1;

r is 0 or 1;

m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;

x8 is 1 to 10;

x9 is 1 to 10;

x10 is 1 to 10;

x11 is 1 to 10;

x12 is 1 to 10;

x13 is 1 to 10;

x14 is 1 to 10;

x15 is 1 to 10; and

x16 is 1 to 10;

x17 is 1 to 10; and

x18 is 1 to 10;

with the proviso that at least one of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is -L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M, and wherein each of the above alkyl, alkenyl, alkynyl, alkylene, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl,

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, or heterocyclylcarbonylalkoxy groups, when present, is independently substituted or unsubstituted.

19. (Original) The compound according to claim 18, wherein m, n and r are each zero, q is 1, p is 2, and Z is $-\text{CH}_2-$.

20. (Original) The compound according to claim 18, wherein m, n and r are each zero, q is 1, p is 2, and Z is $-\text{CH}_2-$, Q^1 is $-\text{OR}^6$, wherein R^6 is hydrogen and Q^5 is fluorine.

21. (Previously Presented) The compound according to claim 18, wherein R^2 and R^3 are each hydrogen.

22. (Original) The compound according to claim 18, wherein Q^1 and Q^2 are each independently selected from the group consisting of $-\text{OR}^6$, $-\text{O}(\text{CO})\text{R}^6$, $-\text{O}(\text{CO})\text{OR}^9$ and $-\text{O}(\text{CO})\text{NR}^6\text{R}^7$.

23. (Original) The compound according to claim 18, wherein Q^4 is halo or $-\text{OR}^6$.


24. (Original) The compound according to claim 18, wherein Q^1 is $-\text{OR}^6$ wherein R^6 is H.

25. (Original) The compound according to claim 18, wherein Q^1 , Q^2 , Q^3 , Q^4 or Q^5 is $-\text{L-M}$.

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

26. (Previously Presented) The compound according to claim 18, wherein Q^1 , Q^2 , Q^3 , Q^4 or Q^5 is $-(C_1-C_{30} \text{ alkylene})-G$.

27. (Withdrawn) The compound according to claim 18, wherein G is selected from the group consisting of:



wherein R, R^a and R^b can be the same or different and each is independently selected from the group consisting of H, -OH, halo, $-NH_2$, azido, alkoxyalkoxy or $-W-R^{30}$;

W is independently selected from the group consisting of $-NH-C(O)-$, $-O-C(O)-$, $-O-C(O)-N(R^{31})-$, $-NH-C(O)-N(R^{31})-$ and $-O-C(S)-N(R^{31})-$;

R^{2a} and R^{6a} can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;

R^{3a} , R^{4a} , R^{5a} , R^{7a} , R^{3b} and R^{4b} can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, $-C(O)alkyl$ and $-C(O)aryl$;

R^{30} is independently selected from the group consisting of R^{32} -substituted T, R^{32} -substituted-T-alkyl, R^{32} -substituted-alkenyl, R^{32} -substituted-alkyl, R^{32} -substituted-cycloalkyl and R^{32} -substituted-cycloalkylalkyl;


R^{31} is independently selected from the group consisting of H and alkyl;

T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;


Reply under 37 CFR 1.116
 Expedited Procedure
 Technology Center 1624
 Attorney Docket No. CV06039US01

R^{32} is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, -OH, phenoxy, -CF₃, -NO₂, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfanyl, alkylsulfonyl, -N(CH₃)₂, -C(O)-NHalkyl, -C(O)-N(alkyl)₂, -C(O)-alkyl, -C(O)-alkoxy and pyrrolidinylcarbonyl; or R^{32} is a covalent bond and R^{31} , the nitrogen to which it is attached and R^{32} form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxy carbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group.

28. (Withdrawn) The compound according to claim 27, wherein G is selected from:



Reply under 37 CFR 1.116
 Expedited Procedure
 Technology Center 1624
 Attorney Docket No. CV06039US01



wherein Ac is acetyl and Ph is phenyl.

29. (Original) The compound according to claim 18, wherein optionally one or more carbon atoms of the $-(C_1-C_{30} \text{ alkylene})-$ radical of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is independently replaced by $-O-$.

30. (Currently Amended) A pharmaceutical composition for the treatment of atherosclerosis, hypercholesterolemia, sitosterolemia, ~~diabetes mellitus, obesity, stroke,~~ lowering a concentration of cholesterol, phytosterol or 5α -stanol in plasma of a ~~mammal, treating demyelination or treating Alzheimer's disease and/or regulating levels of amyloid β peptides in a~~ subject comprising a therapeutically effective amount of a compound of claim 18 in a pharmaceutically acceptable carrier.

31. (Original) A pharmaceutical composition comprising a cholesterol-lowering effective amount of a compound of claim 18 in a pharmaceutically acceptable carrier.

32. (Currently Amended) A method of treating atherosclerosis, hypercholesterolemia, sitosterolemia, ~~diabetes mellitus, obesity, stroke,~~ lowering a concentration of cholesterol, phytosterol or 5α -stanol in plasma of a ~~mammal, treating demyelination or treating Alzheimer's disease or regulating a level of an amyloid β peptide in a~~ subject comprising the step of administering to a subject in need of such treatment an effective amount of a compound of claim 18.

Reply under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Attorney Docket No. CV06039US01

33. (Original) A method of lowering cholesterol level in plasma of a mammal in need of such treatment comprising administering a pharmaceutically effective amount of the compound of claim 18.

{W0301957.1}

26